Neurobiological Technologies Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Neurobiological Technologies are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neurobiological Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong forward indicators, Neurobiological Technologies is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Total Cashflows From Investing Activities | 15.2 M |
Neurobiological |
Neurobiological Technologies Relative Risk vs. Return Landscape
If you would invest (100.00) in Neurobiological Technologies on December 25, 2024 and sell it today you would earn a total of 100.00 from holding Neurobiological Technologies or generate -100.0% return on investment over 90 days. Neurobiological Technologies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Neurobiological, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurobiological Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurobiological Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurobiological Technologies, and traders can use it to determine the average amount a Neurobiological Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NTII |
Based on monthly moving average Neurobiological Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurobiological Technologies by adding Neurobiological Technologies to a well-diversified portfolio.
Neurobiological Technologies Fundamentals Growth
Neurobiological Stock prices reflect investors' perceptions of the future prospects and financial health of Neurobiological Technologies, and Neurobiological Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurobiological Stock performance.
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | (26.24 M) | ||||
| Shares Outstanding | 27.02 M | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0004 X | ||||
| Revenue | 6.03 M | ||||
| EBITDA | 19.54 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Total Asset | 2.58 M | ||||
| Current Liabilities | 73 K | ||||
Things to note about Neurobiological Technologies performance evaluation
Checking the ongoing alerts about Neurobiological Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurobiological Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurobiological Technologies is not yet fully synchronised with the market data | |
| Neurobiological Technologies has some characteristics of a very speculative penny stock | |
| Neurobiological Technologies has a very high chance of going through financial distress in the upcoming years |
- Analyzing Neurobiological Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurobiological Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Neurobiological Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurobiological Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurobiological Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurobiological Technologies' stock. These opinions can provide insight into Neurobiological Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |